← All Sponsors
SPONSOR

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

Total Trials
1
Recruiting
1
Phases
Phase 1
Conditions studied: Spinal Cord InjurySafetyClinical TrialsEfficacyInduced Pluripotent Stem CellsHuman Motor Neuron ProgenitorTransplantation
NCT06976229 Phase 1
Recruiting

Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial

Spinal Cord Injury
China View Trial →